On November 4, Giant Biogene (stock code: 02367.HK), a leader in China's
professional skin care product industry based on bioactive ingredients, was
listed on the main board of the HKEX, becoming the "first collagen stock".
Previously, in October 2021, Giant Biogene completed the only round of
financing since its establishment, and Gaorong Capital participated in the
investment.
Giant Biogene is the pioneer and leader of China's recombinant collagen industry. Dr. Fan Daidi, the core of the R&D team, is one of the leaders in the collagen industry and even in the field of biomedical materials in China. After years of accumulation, Giant Biogene has established a synthetic biology technology platform integrating interdisciplinary scientific research in biotechnology, biochemistry and bioengineering and years of industry expertise. Giant Biogene has successively developed 33 different types of recombinant collagen and successfully mass-produced them. In addition, it has independently developed and produced rare ginsenosides.
Before listing, Giant Biogene's professional skin care products and health food portfolio included 106 SKUs of eight major brands, including Giant Biogene's two flagship brands, Kefumei and Collgene. Collgene and Kefumei are the third and fourth best-selling brands (in terms of retail sales) in China's professional skin care product industry in 2021, respectively.
In 2021, the market size of China's functional skin care products will reach 30.8 billion yuan. Giant Biogene is the second largest professional skin care product company in China in 2021. At the same time, it has been the largest collagen professional skin care product company in China for three consecutive years since 2019 .
While focusing on R&D and product capabilities, Giant Biogene has maintained high-quality performance growth. The data shows that from 2019 to 2021, the company's revenue is RMB 957 million, RMB 1.190 billion and RMB 1.552 billion respectively, with a compound annual growth rate of about 27.39%; Profit reached RMB 723 million and RMB 314 million respectively, showing strong profitability.
